Document is current
Any future updates will be listed below
-
Authors
Laitakari, Anna
Tapio, Joona
Mäkelä, Kari A.
Herzig, Karl-Heinz
Dengler, Franziska
Gylling, Helena
Walkinshaw, Gail
Myllyharju, Johanna
Dimova, Elitsa Y.
Serpi, Raisa
Koivunen, Peppi https://orcid.org/0000-0002-2827-8229
-
Funding
Funding for this research was provided by:
Academy of Finland (266719, 308009, 296498, 251314)
Sigrid Juséliuksen Säätiö
Syöpäjärjestöt
Jane ja Aatos Erkon Säätiö
- License Information
-
More Information
Article History
Received: 25 November 2019
Revised: 6 March 2020
Accepted: 24 March 2020
First Online: 15 April 2020
Compliance with ethical standards
:
: GW is an employee and a shareholder of FibroGen, Inc., which develops HIF-P4H inhibitors as therapeutics. JM owns equity in the company, which supports research by JM.
: All experiments were conducted according to the Finnish Act on Animal Experimentation (62/2006) and approved by the National Animal Experiment Board of Finland.
